Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

Share Price Information for Tissue Regenix Group (TRX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 61.50
Bid: 61.00
Ask: 62.00
Change: 0.00 (0.00%)
Spread: 1.00 (1.639%)
Open: 61.50
High: 61.50
Low: 61.50
Prev. Close: 61.50
TRX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Board Appointment

31 Oct 2005 07:00

Torex Retail PLC31 October 2005 31 October 2005 Torex Retail Plc New Board Appointment Torex Retail plc is pleased to announce the appointment of Michael Meade asFinance Director with effect from 1st November. Michael (aged 45) joins from UBS Investment Bank where he was a senior directorin the investment banking division. He has specialised for many years advisingmid-cap and technology companies in the UK and Europe, including advising TorexPLC up until its sale. Michael is a Chartered Accountant with considerableexperience in the City and will add strength to the Board's strategic thinking. Chris Moore, Chairman of Torex Retail said: "We are delighted to have someone of Michael's calibre and experience join ourBoard. His arrival represents a further strengthening of our senior managementteam and follows the recently announced appointment of Phil Cox. Phil hasalready made a significant impact in his primary Treasury role, as well as in abroader operational management perspective. We have known Michael for manyyears as a trusted adviser and know he will make a valuable contribution to theBoard in its next stage of development. He joins us at a time when we areexperiencing a continuation of the very strong organic growth Torex achieved inthe first six months of 2005 trading. The integration of the recently acquiredbusinesses continues to run ahead of plan, both in time and quantum, and insome areas is already fully completed. Commenting on his appointment Michael Meade said: "Torex Retail is an exciting growth company which I am delighted to be joining.I believe that there exists a great opportunity to continue to build a worldbeating force in retail systems and I look forward to helping the Companyachieve its ambitious goals." Richard Thompson, whilst remaining with the Group, will move into a moreoperationally focussed finance role. The Board wishes to thank Richard for hisconsiderable contribution to the Group through the Group's initial phase ofdevelopment since IPO. Enquiries: Torex Retail 01295 753313 Chris Moore, Executive Chairman Citigate Dewe Rogerson 020 7638 9571Ginny Pulbrook/Seb Hoyle/Lucie Holloway Michael Meade owns 10,000 ordinary shares in Torex Retail PLC. There are nofurther details to be disclosed as per Rule 17 of the AIM rules. About Torex Retail plc Torex Retail is a leading independent provider of cutting edge retail technologysolutions to many of the world's principal retailers. Since the company'sflotation in spring 2004 Torex Retail has achieved rapid growth across all ofits markets and has rigorously pursued its goal of becoming the provider ofchoice. As a result, the company now has a presence in all of the major marketsaround the world and has built a strong platform for future growth in line withits strategy. Torex's Retail's product and solution set spans high street andout-of-town retail as well as the petroleum and convenience sector and with over6,000 customer relationships, including Tesco, Woolworth, Selfridges, Shell andArgos, the company has earned a leading reputation amongst retailers. TorexRetail has more than 2800 staff based in 17 countries. www.torexretail.com. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
25th Apr 20242:27 pmRNSResult of AGM
10th Apr 20247:15 amEQSHardman & Co Research on Tissue Regenix (TRX): Six consecutive periods of >20% growth
5th Apr 20243:52 pmRNSHolding(s) in Company
19th Mar 20247:00 amRNSFinal results for the year ended 31 December 2023
1st Mar 20247:00 amRNSNotice of Results
6th Feb 20247:00 amRNSFirst EU shipment & new distributor agreements
29th Jan 20243:02 pmRNSHolding(s) in Company
25th Jan 20247:00 amRNSTrading update for 2023
23rd Jan 20245:24 pmRNS2023 LTIP Grant
22nd Nov 20234:36 pmRNSHolding(s) in Company
30th Oct 20237:00 amRNSHPRA approval & distribution agreement in Spain
18th Sep 202310:40 amEQSHardman & Co Research on Tissue Regenix (TRX): Continuing postive momentum 1H'23
15th Sep 20234:30 pmRNSDirector/PDMR Shareholding
5th Sep 20237:01 amRNSNew sports medicine product launch
5th Sep 20237:00 amRNSInterim results
31st Aug 20231:45 pmRNSExercise of Options and Total Voting Rights
21st Aug 20237:00 amRNSNotice of interim results
17th Jul 20237:00 amRNSHalf-Year Trading Update
10th Jul 20237:00 amRNSDistribution agreement for OrthoPure® XT in the UK
25th May 20237:00 amRNSDistribution agreement with Australian Allografts
9th May 202312:00 pmRNSHolding(s) in Company
27th Apr 202312:35 pmRNSResult of AGM, Share Reorganisation &TVR
18th Apr 20237:00 amRNSProposed Share Reorganisation Timetable
5th Apr 20232:55 pmEQSHardman & Co Research on Tissue Regenix (TRX): Turning profitable and cash-generative
5th Apr 20237:00 amRNSCEO and CFO Share Purchases
30th Mar 20237:00 amRNSHolding(s) in Company
21st Mar 20237:00 amRNSFinal results for the year ended 31 December 2022
6th Mar 20237:00 amRNSNotice of results and Investor presentation
31st Jan 20237:01 amRNSTrading update for 2022
31st Jan 20237:00 amRNSChange of Adviser
18th Jan 202310:06 amRNSHolding(s) in Company
18th Jan 20237:00 amRNSChinese distribution agreement for OrthoPure® XT
7th Dec 20227:00 amRNSProduct launch in dCELL® division
22nd Nov 20227:00 amRNSDistribution agreement - OrthoPure® XT in Germany
14th Nov 20226:05 pmRNSHolding(s) in Company
7th Nov 20222:35 pmRNSHolding(s) in Company
29th Sep 202210:13 amRNSDirector/PDMR Shareholding
27th Sep 20227:15 amEQSHardman & Co Research on Tissue Regenix (TRX): Operating leverage
7th Sep 20227:00 amRNSHalf-year Report
22nd Aug 20223:31 pmRNSHolding(s) in Company
18th Aug 20225:36 pmRNSHolding(s) in Company
18th Aug 20222:10 pmRNSHolding(s) in Company
11th Aug 20224:30 pmEQSHardman & Co Research: Q&A on Tissue Regenix Group plc: Significantly undervalued which should correct
11th Aug 202212:46 pmRNSHolding(s) in Company
11th Aug 202212:17 pmRNSHolding(s) in Company
11th Aug 20227:00 amRNSConfirmation of Interim Results
5th Aug 20223:19 pmRNSHolding(s) in Company
1st Aug 20223:14 pmRNSHolding(s) in Company
19th Jul 20222:30 pmEQSHardman & Co Research : Tissue Regenix (TRX): Strong 1H’22 sales suggest upside potential
19th Jul 20227:00 amRNSHalf Year Trading Update and Notice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.